Neuroscientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Ltd (NSB) is developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company's current R&D program is focused on developing a treatment for stroke-related brain injury and dementia / Alzheimer's disease, and a diagnostic for early-stage Alzheimer's disease. The Company's lead drug candidate, EmtinB, is a treatment for Alzheimer's disease. The Company also holds patents over 15mS.A., which has several novel capabilities that have the potential to translate into diagnostic processes for Alzheimer's Disease.